Draft Guidance Addresses Company Requests For Rationale Of FDA Decisions
This article was originally published in The Gray Sheet
Executive Summary
The document offers FDA’s interpretation of the terms “substantive summary” and “significant decisions,” both of which appear in new statutory provisions related to the longstanding process for manufacturers to appeal an agency decision.
You may also be interested in...
IDE “Clinical Holds” Can Prompt Industry Request For FDA Rationale
A final guidance on so-called 517A requests, in which companies can request a substantive summary of FDA’s rationale for certain decisions, puts an agency halt of a device trial on the list of actions that qualify for such a request. That is a new addition from the 2013 draft version.
Draft Appeals Guidance Does Not Address Industry’s Main Concerns, Says Device Attorney
FDA’s new draft guidance explains the various routes to appeal a CDRH decision, but doesn’t do much to reform the appeals process, according to one device attorney.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.